MSD

Executive Summary

MSD (Merck & Co., Inc.'s Irish subsidiary) is a key player in the global biopharmaceutical landscape, leveraging over four decades of research excellence to discover and deliver innovative medicines, vaccines, and biologics. Operating from Dublin, MSD Ireland focuses on addressing serious health challenges through leading-edge science, with a portfolio anchored by blockbusters like Keytruda (pembrolizumab) and Gardasil. As a private entity with an estimated valuation of ~$299 billion, the company benefits from the financial and R&D strength of its parent, while maintaining a robust pipeline in oncology, vaccines, and cardiovascular diseases. MSD's commercial product count of three reflects a concentrated strategy on high-impact therapies, and its ongoing investments in biologics and small molecules position it for sustained growth in an increasingly competitive market.

Upcoming Catalysts (preview)

• H2 2026Keytruda label expansion in adjuvant NSCLC (FDA decision)80% success
• Q3 2026Winrevair (sotatercept) phase 3 results in new PAH indication70% success
• Q4 2026Gardasil 9 approval expansion in China (additional age groups)75% success